Management of late-presenting patients with HIV infection

Antiviral Therapy

Volumn 15, Issue SUPPL. 1, 2010, Pages 25-30

  Rockstroh, Jürgen K ^a   Gatell, Jose ^b   Landman, Roland ^c   Antinori, Andrea ^d  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF BARCELONA   (Spain)

^c BICHAT HOSPITAL   (France)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; INDINAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM; DIARRHEA; DRUG PENETRATION; DRUG RESPONSE; DRUG TRANSPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MIXED INFECTION; NAUSEA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REVIEW; THERAPY DELAY; TREATMENT OUTCOME; TREATMENT PLANNING;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 77952071799     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1527     Document Type: Review

References (47)

1. Moreno S, Mocroft A, d'Arminio Monforte A. Medical and societal consequences of late presentation. Antivir Ther 2010; 15 Suppl 1:9-15.
2. Battegay M, Fluckiger U, Hirschel B, Furrer H. Late presentation of HIV-infected individuals. Antivir Ther 2007; 12:841-851.
3. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
4. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
5. Antinori A, Ammassari A, Torti C, et al. Italian consensus statement on management of HIV-infected individuals with advanced disease naive to antiretroviral therapy. Infection 2009; 37:270-282.
6. European AIDS Clinical Society. European AIDS Clinical Society (EACS) Guidelines: clinical management and treatment of HIV infected adults in Europe. (Updated November 2009. Accessed 17 March 2010.) Available from http://www.europeanaidsclinicalsociety.org/guidelinespdf/1-Treatment-of-HIV- Infected-Adults.pdf
7. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents: guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (Updated 1 December 2009.Accessed 13 March 2010.) Available from http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf
8. Battegay M, Fehr J, Fluckiger U, Elzi L. Antiretroviral therapy of late presenters with advanced HIV disease. J Antimicrob Chemother 2008; 62:41-44. (Pubitemid 351865872)
9. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 2009; 4:e5575.
10. Karim SA, Naidoo K, Grobler A, et al. Initiating ART during TB treatment significantly increases survival: results of a randomized controlled clinical trail in TB/HIV-co-infected patients in South Africa. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 36a.
11. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:148-152.
12. Harries AD, Chimzizi R, Zachariah R. Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings. Lancet 2006; 367:944-945.
13. Baalwa J, Mayanja-Kizza H, Kamya MR, John L, Kambugu A, Colebunders R. Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda. Afr Health Sci 2008; 8:190-195.
14. Torok ME, Yen NTB, Chau TT, et al. Randomised controlled trial of imediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis. 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 12-15 September 2009, San Francisco, CA, USA. Abstract H-1224.
15. Makadzange A, Ndhlovu C, Takarinda K, et al. Early vs delayed ART in the treatment of cryptococcal meningitis in Africa. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 36cLB.
16. Diamond C, Taylor TH, Mirad M, Wallace M, Im T, Anton-Culver H. Improved survival and chemotherapy response among patients with AIDS-related NHL receiving highly active antiretroviral therapy. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 826.
17. Martinez V, Caumes E, Gambotti L, et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer 2006; 94:1000-1006.
18. Boffito M, Pillay D, Wilkins E. Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies. Int J Clin Pract 2006; 60:1098-1106. (Pubitemid 44226749)
19. Centers for Disease Control and Prevention. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. MMWR Early Release 2008; 58:1-216.
20. Kelleher T, Cross A, Dunkle L. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine. Clin Ther 1999; 21:1182-1192. (Pubitemid 29380473)
21. Uy J, Yang R, Thiry A, et al. Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated with atazanavir/r and lopinavir/r in the CASTLE study. J Int AIDS Soc 2008; 11:P8.
22. Curkendall SM, Richardson JT, Emons MF, Fisher AE, Everhard F. Incidence of anaemia among HIV-infected patients treated with highly active antiretroviral therapy. HIV Med 2007; 8:483-490. (Pubitemid 47616826)
23. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32:48-56. (Pubitemid 36091484)
24. Pineda JA, Garcia-Garcia JA, Aguilar-Guisado M, et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46:622-630. (Pubitemid 47436106)
25. Lucas GM, Eustace JA, Sozio S, Mentari EK, Appiah KA, Moore RD. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS 2004; 18:541-546. (Pubitemid 38365883)
26. Hänsel A, Bucher HC, Nuesch R, Battegay M. Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients. J Acquir Immune Defic Syndr 2001; 26:191-193. (Pubitemid 32224193)
27. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998; 280:67-71.
28. McGee B, Smith N, Aweeka F. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials 2006; 7:142-153. (Pubitemid 44309004)
29. Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009; 52:56-63.
30. Winston A, Garvey L. Clinical implications of antiretroviral pharmacokinetics and pharmacodynamics in the CNS. HIV Ther 2009; 3:361-367.
31. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
32. Antinori A, Johnson M, Moreno S, Yazdanpanah Y, Rockstroh JK. Report of a European Working Group on late presentation with HIV infection: recommendations and regional variation. Antivir Ther 2010; 15 Suppl 1:31-35.
33. Gatell J. How to implement a consensus definition of 'late presentation'. HIV in Europe 2009. 1-2 November 2009, Stockholm, Sweden. (Updated 2 November 2009. Accessed 25 March 2010.) Available from http://bambuser.com/channel/ HIVinEurope/broadcast/314113
34. HIV in Europe - Working together for optimal testing and earlier care. 2009 Follow-up meeting conference report. 2-3 November 2009. (Updated 10 February 2010. Accessed 17 March 2010.) Available from http://hiveurope.eu/ LinkClick.aspx?fileticket=b8%2FJ9BrkqE%3D&tabid=37
35. Johnson M, Sabin C, Girardi E. Definition and epidemiology of late presentation in Europe. Antivir Ther 2010; 15 Suppl 1:3-8.
36. Trotta MP, Ammasari A, Zaccarelli M, et al. Detrimental effect of current patient-reported drug holidays on long-term sub-optimal treatment outcome in advanced naive subjects initiating ART. 12th European AIDS Conference. 11-14 November 2009, Cologne, Germany. Abstract PE 10.1/10.
37. Wensing AM, van de Vijver D, Angarano G, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966. (Pubitemid 41266791)
38. Sagir A, Oette M, Kaiser R, et al. Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother 2007; 60:843-848. (Pubitemid 47434265)
39. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9:65-71. (Pubitemid 351228129)
40. Bartlett JA, Fath MJ, Demasi R, et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20:2051-2064.
41. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir- based regimen is noninferior to twicedaily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr 2009; 50:474-481.
42. Madero JS, Villasis A, Mendez P. A prospective, randomized, open label trial of efavirenz versus lopinavir/ritonavir based HAART among antiretroviral therapy naive, HIV infected individuals presenting for care with CD4 cell counts. XVII International AIDS Conference. 3-8 August 2008, Mexico City, Mexico. Abstract TUAB0104.
43. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
44. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV- 1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
45. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatmentnaive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679-1688.
46. von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167:1782-1790. (Pubitemid 47403067)
47. Waters LJ, Fisher M, Anderson J, Wood C, Sabin C. Do the disadvantages of late initiation of HAART persist in patients achieving and maintaining viral load (VL) suppression for a year on HAART? J Int AIDS Soc 2008; 11 Suppl 1:O44.